(Q34113899)

31 July 2017

1 reference

title

Oxazaphosphorines: new therapeutic strategies for an old class of drugs (English)

1 reference

31 July 2017

Gareth J Veal

4

0 references

Angelo Paci

object named as

Angelo Paci

6

0 references

author name string

Bérénice Giraud

1

1 reference

31 July 2017

Guillaume Hebert

2

1 reference

31 July 2017

Alain Deroussent

3

1 reference

31 July 2017

Gilles Vassal

5

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Expert Opinion on Drug Metabolism & Toxicology

31 July 2017

published in

1 reference

31 July 2017

volume

6

1 reference

31 July 2017

issue

8

1 reference

31 July 2017

page(s)

919-938

1 reference

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Metabolism and pharmacokinetics of oxazaphosphorines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Cyclophosphamide toxicity. Characterising and avoiding the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Trofosfamide in the palliative treatment of cancer: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Clinical and cellular pharmacology in relation to solid tumours of childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Design of new oxazaphosphorine anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Anodic oxidation of ifosfamide and cyclophosphamide: a biomimetic metabolism model of the oxazaphosphorinane anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Investigations on the pharmacokinetics of trofosfamide and its metabolites-first report of 4-hydroxy-trofosfamide kinetics in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Metabolism of oxazaphosphorines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

The partitioning of phosphoramide mustard and its aziridinium ions among alkylation and P-N bond hydrolysis reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Isophosphoramide Mustard and Its Mechanism of Bisalkylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Hallucinations and ifosfamide-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Ifosfamide, mesna, and nephrotoxicity in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Enantioselective induction of cyclophosphamide metabolism by phenytoin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Glutathione diminishes the anti-tumour activity of 4-hydroperoxycyclophosphamide by stabilising its spontaneous breakdown to alkylating metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

The interaction of glutathione with 4-hydroxycyclophosphamide and phosphoramide mustard, studied by 31P nuclear magnetic resonance spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Selective protection by stably transfected human ALDH3A1 (but not human ALDH1A1) against toxicity of aliphatic aldehydes in V79 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Toxicity of chloroacetaldehyde is similar in adult and pediatric kidney tubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Mechanisms of DNA sequence selective alkylation of guanine-N7 positions by nitrogen mustards

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Apoptosis induced by anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Cyclophosphamide cystitis—Identification of acrolein as the causative agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Use of mesna to prevent ifosfamide-induced urotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Chronic ifosfamide nephrotoxicity in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Long-term evaluation of Ifosfamide-related nephrotoxicity in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

The influence of ifosfamide scheduling on acute nephrotoxicity in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Ifosfamide induced encephalopathy: 15 observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Ifosfamide neurotoxicity: an atypical presentation with psychiatric manifestations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Subacute central nervous system degeneration in a child: an unusual manifestation of ifosfamide intoxication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Ifosfamide-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Ifosfamide by continuous infusion to prevent encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Ifosfamide toxicity in cultured proximal renal tubule cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

A tubule cell model for ifosfamide nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Targets of chloroacetaldehyde-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Chloroacetaldehyde- and acrolein-induced death of human proximal tubule cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Painful peripheral neuropathy after treatment with high-dose ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Methylene blue for management of Ifosfamide-induced encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Cytochrome P450-based cancer gene therapy: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Enzyme-catalyzed activation of anticancer prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.487861

10.1517/17425255.2010.487861

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference